Sort   by:  
 Page size 
A use case of the benign HLA-Ligand-Atlas is the prioritization of tumor-associated targets for e.g. peptide vaccination. Based on three glioblastoma samples, we illustrated how many of these peptides are covered in the benign dataset. The experimental and computational workflow for the isolation an...
ORGANISM(S): Homo sapiens (Human) 
2021-04-16 | PXD020186 | Pride
In recent years, several approaches have been taken in the peptide-based immunotherapy of metastatic renal cell carcinoma (RCC), although little is known about HLA presentation on metastases compared to primary tumor and normal tissue of RCC. In this study we compared primary tumor, normal tissue an...
ORGANISM(S): Homo sapiens 
The human leukocyte antigen (HLA) complex regulates the adaptive immune response by showcasing the intracellular and extracellular protein content to the immune system. T cells recognize these HLA-presented peptides as self or foreign and can elicit an immune response. In this work, we describe the...
ORGANISM(S): Homo sapiens (Human) 
2021-04-16 | PXD019643 | Pride
The human leukocyte antigen (HLA) complex regulates the adaptive immune response by showcasing the intracellular and extracellular protein content to the immune system. T cells recognize these HLA-presented peptides as self or foreign and can elicit an immune response. In this work, we describe the...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-10-31 | MSV000096271 | MassIVE
The human leukocyte antigen (HLA) complex regulates the adaptive immune response by showcasing the intracellular and extracellular protein content to the immune system. T cells recognize these HLA-presented peptides as self or foreign and can elicit an immune response. In this repository, we extend ...
ORGANISM(S): Homo sapiens (Human) 
2025-09-04 | PXD024837 | Pride
Gene and protein sequence features augment HLA class I ligand predictions (mRNA sequencing)
Gene and protein sequence features augment HLA class I ligand predictions (ribosome profiling)
The sensitivity of malignant tissues to T cell-based cancer immunotherapies is dependent on the presence of targetable HLA class I ligands on the tumor cell surface. Peptide intrinsic factors, such as HLA class I affinity, likelihood of proteasomal processing, and transport into the ER lumen have al...
ORGANISM(S): Homo sapiens 
2023-01-08 | GSE210999 | GEO
The sensitivity of malignant tissues to T cell-based cancer immunotherapies is dependent on the presence of targetable HLA class I ligands on the tumor cell surface. Peptide intrinsic factors, such as HLA class I affinity, likelihood of proteasomal processing, and transport into the ER lumen have al...
ORGANISM(S): Homo sapiens 
2023-01-08 | GSE210998 | GEO
Sort   by:  
 Page size